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complacent. We obviously had not recognised the
perception that we represented the regime and were its
mouthpiece; that the situation was more sensitive than we
had realised; that feelings of hurt and anguish ran deep; that
we had in fact been resigned to accepting an atrocious
situation. I apologised for this complacency, for the loss of
dignity our colleagues had suffered for so long, and for all
our errors of omis~ion, and expressed the heartfelt hope that
we could look forward to a future of reconciliation and join
hands in peace and friendship. It is with very great joy that
in the subsequent two years I have seen such forgiveness
and willingness to put the past aside, both in medical circles
and in our country as a whole.
J.Adno
Suite 6. Park Lane Clinic
Parktown
Johannesburg
1. Van der Unde I. Sometimes having to say you're sorry (Izindaba). S Atr Med J
1995; 85: 715.
The effectiveness and cost of exogenous
pulmonary surfactant replacement
therapy
To the Editor: The articles"" recently published on surfactant
replacement therapy (SR1) in the treatment of newborn
infants with hyaline membrane disease (HMD) being
ventilated in a country with limited health resources are both
timeous and urgently needed. Surfactant, being an
expensive drug, needs to be administered in the most cost-
effective fashion and for this reason research guidelines for
its administration in South Africa are needed. We are
concerned that the discussions of this series of articles do
not sufficiently emphasise their limitations, as well as the
enormous impact of SRT on survival rates and other
neonatal morbidities in newborn infants ventilated with
HMD. It has been stated that SRT is one of the many recent
triumphs of medical science.s The efficacy of both natural
and synthetic exogenous surfactant for prevention and
treatment of HMD has been confirmed in several large
randomised clinical trials." The impact on mortality in the
USA since its release in 1990 has been dramatic, with
decreases of 15% in overall neonatal mortality and as high
as 50% in high-risk groups such as infants delivered at less
than 29 weeks' gestation or weighing less than 1 200 g. The
costs saved are also considerable, with Soli et a/. 8 reporting
a reduction of US$ 3 319 per 28-day survivor for babies
who received exogenous SRT (natural surfactant) versus
sham-air. Calculations that take into account both the offset
of savings incurred by increasing numbers of very-Iow-birth-
weight infants and the higher costs for babies who survived
instead of dying, suggest that the USA saved an estimated
$90 million (1985 - 1990).9 Like the local studies, these
studies do not show a net reduction in the total number of
days of hospitalisation!·4
Since these calculations might not be applicable to a
country with limited financial resources, their use in South
Africa requires investigation. The indications investigated by
Ballot et al.' to prevent the unnecessary use of SRT
stimulate further debate. In the group of neonates with
severe HMD (Table Ill, group 2) where SRT was withheld for
longer than 6 hours, the mortality rate was an unacceptable
38% (5/13). This did not significantly differ from the mortality
rate (22%, 2/9) experienced in the group of babies (group 1)
who received early SRT. This lack of difference is probably
due to a type 2 statistical error (too few babies enrolled). In
neonates with severe HMD the delayed administration led to
. a 15% reduction in SRT use. The authors acknowledge that
this is not justified and that SRT should be administered
early to neonates with severe HMD. The study design did
not allow for the inclusion of a group of neonates with
moderate HMD (fractional inspired oxygen concentration
(Fi02) < 0,75) who received SRT within 6 hours of birth. 'lYe
consider that this is a major limitation, since we do not know
whether there would have been a reduction in the morbidity
(duration of ventilation, pneumothorax rate or length of
hospitalisation) of these neonates when compared with the
neonates who received SRT after 6 hours. These data·;are
essential for formulating guidelines and calculating CQsts.
A subsequent article by Davies et a/. 4 assessed and
compared the cost and effectiveness of a policy of delp.yed
surfactant replacement therapy (SR1) in a group of bgbies
with HMD versus that of a historical control group using
guidelines similar to those developed by Ballot et al. 2 The
authors show that SRT (Survanta; Abbott) led to an increase
in the total cost of treating a baby ventilated for HMD. A
critical review of these published data is essential, as they
could have far-reaching consequences for the effective care
of neonates with HMD in southern Africa.
The authors studied ventilated babies, selected to receive
SRT according to their initial oxygen requirements
(arterial/alveolar oxygen ratio), and compared them with a
retrospective group of babies ventilated at their institution
before the introduction of SRT. As the authors report, there
are significant demographic differences between the SRT and
control groups. The babies in the SRT group were of lower
birth weight, received less antenatal care (72% v. 15%
unbooked) and included more black infants (74% v. 28%).
The infants in the SRT group probably had more severe
disease, as reflected by the fact that more of them needed
inotropic support and paralysis, although no recognised
objective evidence of the severity of the HMD such as
arterial/alveolar oxygen ratio for the two groups is presented.
We want to emphasise firstly the differences between the
SRT and control groups and secondly the limitations of the
indications used for the administration of SRT. We believe
that the conclusions drawn from the data should be
interpreted with caution. It is not clear to us why the use of
SRT did not lead to a reduction in mortality and morbidity,
as has been universally reported. Clarification for this could
be found in a faulty study design or in the neonates selected
to receive SRT. Ballot et al. 2 included 1 baby with a
congenital heart lesion, 4 with presumed bacterial
pneumonia, and, as pointed out in the article, an unknown
number of severely asphyxiated babies.
To date more than 35 randomised controlled trials on SRT
have now been conducted involving more than 6 000 babies
and have demonstrated a consistent 40% reduction in the
odds of neonatal death after surfactant treatment."
Treatment of established HMD offers the advantage of
limiting the number of individuals treated to only those
babies with definite HMD. The most appropriate time to treat
manifest (rescue) HMD seems to be within the first 6 hours
after birth. Thereafter various factors may be operative in
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inactivating the surface properties of exogenous surfactant.
Lang et al. 10 found in stepwise discriminant analysis that
rescue therapy with surfactant before 4 hours of age was
associated with improved outcome compared with that in
infants rescued at a later stage.
Respiratory distress syndrome is a complex problem not
solely attributed to surfactant deficiency. In addition,
mortality often results from causes other than respiratory
failure, limiting the impact on overall mortality. The
significant differences observed in mortality rates between
severe and mild/moderate HMD groups in the study of Ballot
et al. 2 could be accounted for by the inclusion of babies with
diseases other than HMD.
There is now irrefutable evidence that the administration
of steroids to women expected to deliver preterm reduces
the incidence of HMD. It was estimated in one controlled
trial of antenatal steroids that prophylaxis more than halved
subsequent hospital costs in the group that had received the
drugs." This is a more cost-effective approach than
administering SRT for HMD. In the article by Davis et aI. 4
only 5% of mothers received antenatal steroids. The
greatest saving in the administration of SRT would be
achieved by ensuring that all mothers in premature labour
« 34 weeks) receive antenatal steroids.
Until controlled trials are conducted in South Africa to
address some of the limitations highlighted by the series of
publications from the University of the Witwatersrand,HI it is
our opinion that this form of life-saving and efficacious
therapy should not be withheld from neonates with
moderate and severe HMD.
J. Smith
C. Pieper
R. P. Gie
Department of Paediatrics and Child Health
University of Stellenbosch
TYgerber9, W. Cape
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Professor Rothberg and Drs Davies and Ballot reply: The
response from Tygerberg characterises the philosophical
debate which has taken place between that neonatal unit
and the Johannesburg unit since the advent of surfactant
replacement therapy. The positions can be summarised as
follows: Tygerberg promotes aggressive intervention, using
survival as a major indicator of success; Johannesburg
promotes targeted intervention, keeping in mind the
consequences of salvaging additional babies within a
system which cannot cope with a pre-existing burden.
Smith et al. are correct in their analyses of the
predominantly North American experience. However, they do
not emphasise the point that the major impact has been in
those babies who are usually not ventilated in this country
because of resource constraints. Several studies and
analyses have shown dramatic results in babies weighing
between 500 and 1 000 g.'2 In fact, the reference cited by
Tygerberg to support their argument" shows quite clearly
that the surfactant-related effect on mortality is inversely
related to birth weight; while there is a significant difference
.between pre- and post-surfactant mortality rates for babies
weighing less than 1 000 g (41,5% v. 34,7%; P < 0,01),
there is no difference for babies weighing 1 000 g or more
(9,9% v. 8,3%; P = 0,2). As Smith et al. well know, most
academic units in South Africa will not routinely ventilate
babies weighing less than 1 000 g.
The paper by Schwartz et al. 3 also includes an interesting
comment under 'Methods', Le. that the 14 units underwent a
25% increase in size during the period under review,
although the number of births did not change. This
requirement to 'upsize' represents the cost of additional
survivors, and, in the context of the Johannesburg academic
experience, would represent a cost that could not currently
be considered. In similar vein, Smith4 recently presented
data showing that providing CPAP to those neonates who
'don't qualify for ventilation' increases their chance of
survival by some 300%. Again, the question is not one of
viability or availability of ventilators for this group of tiny
neonates; as always it is one of being able to accept the
consequences of 'unrationed' care, in particular physically
being able to accommodate more babies.
While the authors of the series of papers on surfactant
replacement therapy5-ll will continue to defend their general
argument against the Tygerberg plea for unrestricted use,
they do acknowledge an important point made by the
Tygerberg group. The Johannesburg studies took a historic
experience of 87% survival in surfactant-deficient infants
and asked whether it was necessary to treat 100% of
neonates with surfactant to enhance an already acceptable
survival figure. The group decided on a strategy to identify
only those who 'qualified', and ended up treating only 59%
of infants. The Tygerberg group rightly points out that an
ideal next step would be a study to compare the 41 %
currently denied surfactant with a similar group given
surfactant within the first few hours of life. Only then would it
really be possible to comment on the cost or cost-benefit of
the Johannesburg protocol, but in the interim it would seem
that some savings are achieved by not treating all eligible
infants, and outcome is not significantly compromised.
In terms of any savings related to surfactant use, it must
be recognised that the basis for calculation in the South
African academic context is solely 'global cost per bed
day'! Therefore, if there are only marginal differences in the
duration of stay at the various levels of care,' surfactant use
will obviously represent an additional cost. If, on the other
hand, one were able accurately to assess specific, itemised
differences in resource utilisation for groups pre- and post
surfactant as was done in the US review,> savings might well
emerge. Unfortunately such analysis remains problematic in
the context of our public hospitals.
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Containing costs
To the Editor: At a recent meeting with the National
Pathologists Group earlier this year a few issues were
raised. Firstly, they complain that most request forms are
received without any clinical details. Were these included,
they could help the pathologist to consider the relevance of
the tests requested and possibly advise the clinician
accordingly.
The second point raised was whether doctors knew the
costs of any tests they requested.
Both these items are of importance in the endeavour to
contain costs, the main factor that will enable private care to
continue.
E. D. Sonnenfeld
MedIcal Adviser
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Fig. 1. Annual incidence and outcome in patients with puln,onary
or disseminated tuberculosis requiring care in the respiratory ICU
at Groote Schuur Hospital.
concern will be the increasing demands on already Iiniited
ICU resources, and the considerable health risk to staff.s The
cost of treating these patients may be estimated from a
previous cost analysis in this unit at R20 388 per survivor."
Additional expenditure will also be needed to help prevent the
disease from spreading from patients requiring mechanical
ventilation to staff and other patients.7
If these increased ICU needs are not met increasing triage
of patients will be necessary, and this will inevitably result in
some patients who would only survive with intensive care
treatment not being given this therapy.
Medscheme (Pty) Lld
300 Kent Avenue
Randburg, Gauteng
P. D. Potgieter
Intensive Care Unit
Groote Schuur Hospital
Cape Town
The influence of the tuberculosis
epidemic on ICU resources
To the Editor: Over the past decade there has been a world-
wide increase in the incidence of tuberculosis. Nowhere has
this been greater than in the Western Cape, where the
incidence of tuberculosis is 472/100 000 workers in industry
and the disease causes 7% of deaths between the ages of 7
and 60 years.
'
'> The number of patients with pulmonary or
disseminated tuberculosis admitted to the respiratory
intensive care unit at Groote Schuur Hospital has increased
dramatically over the past 10 years, with 164 patients being
admitted, and during 1993 and 1994 tuberculosis contributed
to 6% of admission (Fig. 1.) The mortality in these patients
(29%) is remarkable considering the severity of this slowly
responding infective disease; unfortunately we are as yet
unable to predict which patients will do well, so as to
facilitate appropriate triage. Of interest is that this increase is
not a result of HIV infection or multidrug-resistant
tuberculosis, as only 1 patient was HIV-positive, and one had
multiresistant disease.3 If this increase continues the numbers
could be predicted to double in the next 3 - 5 years; however,
as HI infection influences this trend, even greater numbers
could be expected.' While this increase will place a
considerable burden on community health services, there will
be an inevitable influence on other specialised areas. Of great
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Financial support for SAMJ research, 1994
To the Editor: Several national and international initiatives
aimed at setting priorities for health and medical research
have highlighted the need for accurate data on the sources
of funding used for research. Such data are important for
several reasons: (I) priority-setting processes need to involve
funders if they are to be successful; and (if) certain funding
sources may adversely influence the medium- and long-term
direction and impact of research.
In South Africa, the ministerially appointed Committee into
Essential National Health Research, in attempting to
document funding sources, identified the need for a more
thorough review of funding sources to be undertaken. This
brief report contributes to that need.
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